Literature DB >> 28876979

General anaesthesia for patients with a history of a contrast medium-induced anaphylaxis: a useful prophylaxis?

Ingrid Boehm1,2, Knud Nairz1, John Morelli3, Patricia Silva Hasembank Keller4, Johannes Thomas Heverhagen1,2.   

Abstract

Contrast-enhanced radiological examinations are important diagnostic tools in modern medicine. Currently, all approved and available iodinated and gadolinium-based contrast agents are safe and well-tolerated by most patients. However, approximately 2% of patients receiving iodinated contrast media exhibit hypersensitivity reactions. Patients with a history of such a reaction are at increased risk upon reexposure. Therefore, they are subjected to a prophylaxis such as injection of antiallergy drugs or general anaesthesia. The latter procedure is expensive, can burden the patients organism, and besides lacks objective verification. Therefore, the purpose of our review paper is to present and discuss the background and the previous practice, as well as to provide a proposal for a safe individual patient management.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28876979      PMCID: PMC5963380          DOI: 10.1259/bjr.20160647

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  25 in total

1.  [Anaphylactoid complications of iodide contrast media in arteriography of the lower extremities during general anesthesia].

Authors:  J Fays; H P Stehlin; A Treheux
Journal:  Ann Anesthesiol Fr       Date:  1976

2.  Adverse reactions following administration of an ionic iodinated contrast media in anesthetized dogs.

Authors:  Amanda Vance; Matthew Nelson; Erik H Hofmeister
Journal:  J Am Anim Hosp Assoc       Date:  2012-04-03       Impact factor: 1.023

3.  Adverse reactions following administration of contrast media for diagnostic imaging in anaesthetized dogs and cats: a retrospective study.

Authors:  Stefania Scarabelli; Peter Cripps; Eva Rioja; Briony Alderson
Journal:  Vet Anaesth Analg       Date:  2016-01-19       Impact factor: 1.648

Review 4.  Computed tomography--an increasing source of radiation exposure.

Authors:  David J Brenner; Eric J Hall
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

5.  [Contrast medium induced anaphylaxis and prevention by selecting a compatible contrast agent].

Authors:  I Böhm; H Schild
Journal:  Rofo       Date:  2008-10-10

6.  Cardiac arrest after administration of Omnipaque radiocontrast medium during endoluminal repair of abdominal aortic aneurysm.

Authors:  V Brown; B Brandner; J Brook; M Adiseshiah
Journal:  Br J Anaesth       Date:  2002-01       Impact factor: 9.166

7.  Adverse reactions to non-ionic iodinated contrast media do occur during general anesthesia.

Authors:  J P Jantzen; B Wangemann; G Wisser
Journal:  Anesthesiology       Date:  1989-03       Impact factor: 7.892

8.  Breakthrough adverse reactions to low-osmolar contrast media after steroid premedication.

Authors:  K S Freed; R A Leder; C Alexander; D M DeLong; M A Kliewer
Journal:  AJR Am J Roentgenol       Date:  2001-06       Impact factor: 3.959

9.  Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010.

Authors:  J-M Renaudin; E Beaudouin; C Ponvert; P Demoly; D-A Moneret-Vautrin
Journal:  Allergy       Date:  2013-06-06       Impact factor: 13.146

10.  Safety of Blood Pool Contrast Agent Administration in Children and Young Adults.

Authors:  Cynthia K Rigsby; Andrada R Popescu; Paige Nelson; R Jason Orr; Emma E Boylan; Samantha Schoeneman; R Andrew deFreitas
Journal:  AJR Am J Roentgenol       Date:  2015-11       Impact factor: 3.959

View more
  1 in total

1.  A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions.

Authors:  Andrea Mencarelli; Merry Gunawan; Kylie Su Mei Yong; Pradeep Bist; Wilson Wei Sheng Tan; Sue Yee Tan; Min Liu; Edwin Kunxiang Huang; Yong Fan; Jerry Kok Yen Chan; Hae Woong Choi; Soman N Abraham; Qingfeng Chen
Journal:  J Leukoc Biol       Date:  2020-01-10       Impact factor: 6.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.